Sanofi GCVRZ 深 沪
已收盘 03-26 16:00:00 美东时间
0.8711
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 总市值 1113.52亿
- 52周最高 0.882
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 总股本 1278.30亿
- 历史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.153
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Scribe Therapeutics announced that its CEO, Benjamin Oakes, will participate in the Guggenheim Healthcare Innovation Conference on Nov. 10 and deliver a presentation at the Stifel Healthcare Conference on Nov. 11. The company will also host investor meetings during London Life Sciences Week from Nov. 15-20. Scribe, a clinical-stage biotech company, focuses on developing CRISPR-based genetic medicines to treat cardiometabolic diseases, with its le...
11-05 13:00
Sanofi Discontinues Nurix Therapeutics STAT6 Degrader Program
The latest update is out from Nurix Therapeutics ( ($NRIX) ). On November 3, 20...
11-04 05:57
Regeneron and Sanofi Update Long-Term Pediatric Dupixent Study
Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their...
11-04 00:30
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
Nurix Therapeutics announced that Sanofi has discontinued the Phase 1 clinical trial of SAR448272, an oral STAT6 degrader, and terminated the program. As a result, Nurix will not receive future milestone payments or royalties related to SAR448272. However, the company remains eligible for payments from other licensed programs under the collaboration. Nurix has a strong cash runway of $1.1 billion, sufficient to fund operations into 2029. The comp...
11-03 21:01
Recursion Reports Clinical Progress as Sanofi Options First Candidate
The latest update is out from Recursion Pharmaceuticals ( ($RXRX) ). On Novembe...
11-03 06:24
Regeneron Stock Forecast: REGN Jumps 13% as Full Dupixent Profits Kick In, With $930.46 the Next Test
TradingKey - Regeneron stock forecast: REGN jumped 13.33% after a big Q3 beat driven by full Dupixent profits, with $930.46 the next test and RSI overbought.
11-02 12:30
Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It
Sanofi SA (NASDAQ:SNY) on Friday reported third-quarter sales of $16.623 billion (14.444 billion euros), beating the consensus of $15.23 billion. Sales increased 16.2% year over year, up 14.3% in constant currency. The company reported adjusted EPS of 3.55 euros per share, or $2.04 per ADS, beating ...
10-30 23:09
Sanofi Q3 Adj. EPS $2.04 Beats $1.63 Estimate, Sales $16.623B Beat $15.230B Estimate
Sanofi (NASDAQ:SNY) reported quarterly earnings of $2.04 per share which beat the analyst consensus estimate of $1.63 by 25.15 percent. This is a 22.16 percent increase over earnings of $1.67 per share from the same period last year. The company reported quarterly sales of $16.623 billion which beat...
10-30 15:50
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Regeneron has extended its agreement with BARDA to supply additional doses of Inmazeb, its Ebola treatment, through 2031, adding approximately $270 million in value. Inmazeb, the first FDA-approved Ebola treatment, has shown significant efficacy in reducing mortality. Separately, Regeneron is advancing maftivimab, a component of Inmazeb, as a potential treatment for Bundibugyo ebolavirus, with preclinical data supporting its effectiveness. The co...
10-26 11:00
Sanofi’s New Oral Alzheimer’s Drug Enters Mid-Stage Trials: What Investors Should Watch
Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi is...
10-24 00:30
